Rod McNeil

Independent Journalist and Consultant

Latest Contribution

Diagram showing new two-year data from TENAYA and LUCERNE demonstrate durable efficacy with faricimab using a treat-and-extend approach up to Q16W (4-monthly) dosing in patients with nAMD

Broadening of treatment options for potentially blinding retinal conditions

2 August 2022 | | Ophthalmology

Rod McNeil provides an update on a promising bispecific antibody recently approved for treatment of neovascular age-related macular degeneration (nAMD) and diabetic macular oedema (DMO) and considers emerging developments in biosimilars to established anti-vascular endothelial growth factor (anti-VEGF) therapies, including...

Diagram showing NICE glaucoma guidance, updated January 2022.

Ambitions for sustainable service recovery amidst an escalating post-COVID backlog

5 April 2022 | | Ophthalmology, COVID-19

Rod McNeil reviews plans, activity and solutions to better address the post-COVID backlog and bolster sustainable service recovery. Ophthalmology was the busiest outpatient specialty during the three years to March 2020 across the English NHS and again recorded the highest...

Photo showing the PAUL glaucoma drainage device. Image courtesy of Advanced Ophthalmic Innovations.

What’s new in glaucoma? Clinical trials drive practice changes, surgical advancements gather pace

1 December 2021 | | Ophthalmology, Glaucoma

Rod McNeil reviews the latest developments in the treatment of glaucoma in the UK. Primary open-angle glaucoma (POAG), which accounts for over two-thirds of all glaucoma cases, has an estimated UK prevalence in 2017 of approximately 2% of people over...